nach oben

Journal of Endocrinological Investigation

Erschienen in:

01.12.2019 | Short Review

Overview of results from the Vitamin D Assessment (ViDA) study

verfasst von: R. K. R. Scragg

Erschienen in: Journal of Endocrinological Investigation | Ausgabe 12/2019

Einloggen, um Zugang zu erhalten

Abstract

Background

The Vitamin D Assessment (ViDA) study is a randomised, double-blind, placebo-controlled trial to evaluate the efficacy of monthly vitamin D supplementation in reducing the incidence of a range of acute and chronic diseases and intermediate outcomes.

Methods

The study was carried out in Auckland, New Zealand, among 5110 adults, aged 50–84 years, who were followed for a median 3.3 years. The intervention was vitamin D3 (2.5 mg or 100,000 IU) or placebo softgel oral capsules, mailed monthly to participants’ homes, with two capsules sent in the first mail-out post-randomisation (i.e. 200,000 IU bolus, or placebo), followed 1 month later (and thereafter monthly) with 100,000 IU vitamin D3 or placebo capsules. Outcomes were monitored through routinely collected health data and self-completed questionnaires.

Results

The results showed no beneficial effect of vitamin D supplementation on incidence of cardiovascular disease, falls, non-vertebral fractures and all cancer. However, beneficial effects from vitamin D supplementation were seen: for persistence with taking statins in participants on long-term statin therapy; and also in bone mineral density and arterial function in participants with low 25-hydroxyvitamin D levels, and in lung function among ever smokers (especially if vitamin D deficient). The latter findings are consistent with several previous studies,

Conclusion

Monthly high-dose vitamin D supplementation does not prevent a range of diseases, but may be beneficial for some intermediate outcomes in people who are vitamin D deficient.

Trial registration

Australian New Zealand Clinical Trials Registry identifier: ACTRN12611000402943.

Wang TJ, Pencina MJ, Booth SL, Jacques PF, Ingelsson E, Lanier K, Benjamin EJ, D’Agostino RB, Wolf M, Vasan RS (2008) Vitamin D deficiency and risk of cardiovascular disease. Circulation 117(4):503–511CrossRefPubMed

Melamed ML, Michos ED, Post W, Astor B (2008) 25-Hydroxyvitamin D levels and the risk of mortality in the general population. Arch Intern Med 168(15):1629–1637. https://doi.org/10.1001/archinte.168.15.1629 CrossRefPubMedPubMedCentral

Scragg R, Sowers M, Bell C (2004) Serum 25-hydroxyvitamin D, diabetes, and ethnicity in the Third National Health and Nutrition Examination Survey. Diabetes Care 27(12):2813–2818CrossRefPubMed

Scragg R, Sowers M, Bell C (2007) Serum 25-hydroxyvitamin D, ethnicity, and blood pressure in the Third National Health and Nutrition Examination Survey. Am J Hypertens 20(7):713–719CrossRefPubMed

Black PN, Scragg R (2005) Relationship between serum 25-hydroxyvitamin D and pulmonary function in the Third National Health and Nutrition Examination Survey. Chest 128(6):3792–3798CrossRefPubMed

Ginde AA, Mansbach JM, Camargo CA Jr (2009) Association between serum 25-hydroxyvitamin D level and upper respiratory tract infection in the Third National Health and Nutrition Examination Survey. Arch Intern Med 169(4):384–390. https://doi.org/10.1001/archinternmed.2008.560 CrossRefPubMedPubMedCentral

Autier P, Gandini S (2007) Vitamin D supplementation and total mortality: a meta-analysis of randomized controlled trials. Arch Intern Med 167(16):1730–1737CrossRefPubMed

Wactawski-Wende J, Kotchen JM, Anderson GL, Assaf AR, Brunner RL, O’Sullivan MJ, Margolis KL, Ockene JK, Phillips L, Pottern L, Prentice RL, Robbins J, Rohan TE, Sarto GE, Sharma S, Stefanick ML, Van Horn L, Wallace RB, Whitlock E, Bassford T, Beresford SA, Black HR, Bonds DE, Brzyski RG, Caan B, Chlebowski RT, Cochrane B, Garland C, Gass M, Hays J, Heiss G, Hendrix SL, Howard BV, Hsia J, Hubbell FA, Jackson RD, Johnson KC, Judd H, Kooperberg CL, Kuller LH, LaCroix AZ, Lane DS, Langer RD, Lasser NL, Lewis CE, Limacher MC, Manson JE (2006) Calcium plus vitamin D supplementation and the risk of colorectal cancer. N Engl J Med 354(7):684–696CrossRefPubMed

Jackson RD, LaCroix AZ, Gass M, Wallace RB, Robbins J, Lewis CE, Bassford T, Beresford SA, Black HR, Blanchette P, Bonds DE, Brunner RL, Brzyski RG, Caan B, Cauley JA, Chlebowski RT, Cummings SR, Granek I, Hays J, Heiss G, Hendrix SL, Howard BV, Hsia J, Hubbell FA, Johnson KC, Judd H, Kotchen JM, Kuller LH, Langer RD, Lasser NL, Limacher MC, Ludlam S, Manson JE, Margolis KL, McGowan J, Ockene JK, O’Sullivan MJ, Phillips L, Prentice RL, Sarto GE, Stefanick ML, Van Horn L, Wactawski-Wende J, Whitlock E, Anderson GL, Assaf AR, Barad D (2006) Calcium plus vitamin D supplementation and the risk of fractures. N Engl J Med 354(7):669–683CrossRefPubMed

10.

Newmark HL, Heaney RP (2006) Calcium, vitamin D, and risk reduction of colorectal cancer. Nutr Cancer 56(1):1–2CrossRefPubMed

11.

Scragg R (2018) Limitations of vitamin D supplementation trials: why observational studies will continue to help determine the role of vitamin D in health. J Steroid Biochem Mol Biol 177:6–9. https://doi.org/10.1016/j.jsbmb.2017.06.006 CrossRefPubMed

12.

Heaney RP (2008) Vitamin D in health and disease. Clin J Am Soc Nephrol 3(5):1535–1541. https://doi.org/10.2215/cjn.01160308 CrossRefPubMedPubMedCentral

13.

Meyer HE, Holvik K, Lips P (2015) Should vitamin D supplements be recommended to prevent chronic diseases? BMJ 350:h321. https://doi.org/10.1136/bmj.h321 CrossRefPubMed

14.

Manson JE, Bassuk SS, Lee IM, Cook NR, Albert MA, Gordon D, Zaharris E, Macfadyen JG, Danielson E, Lin J, Zhang SM, Buring JE (2012) The VITamin D and OmegA-3 TriaL (VITAL): rationale and design of a large randomized controlled trial of vitamin D and marine omega-3 fatty acid supplements for the primary prevention of cancer and cardiovascular disease. Contemp Clin Trials 33(1):159–171. https://doi.org/10.1016/j.cct.2011.09.009 CrossRefPubMed

15.

Scragg R, Waayer D, Stewart AW, Lawes CM, Toop L, Murphy J, Khaw KT, Camargo CA Jr (2016) The Vitamin D Assessment (ViDA) Study: design of a randomized controlled trial of vitamin D supplementation for the prevention of cardiovascular disease, acute respiratory infection, falls and non-vertebral fractures. J Steroid Biochem Mol Biol 164:318–325. https://doi.org/10.1016/j.jsbmb.2015.09.010 CrossRefPubMed

16.

Reid IR, Bolland MJ, Grey A (2010) Does calcium supplementation increase cardiovascular risk? Clin Endocrinol (Oxf) 73(6):689–695. https://doi.org/10.1111/j.1365-2265.20 CrossRef

17.

Scragg R, Stewart AW, Waayer D, Lawes CMM, Toop L, Sluyter J, Murphy J, Khaw KT, Camargo CA Jr (2017) Effect of monthly high-dose vitamin D supplementation on cardiovascular disease in the vitamin D assessment study: a randomized clinical trial. JAMA Cardiol 2(6):608–616. https://doi.org/10.1001/jamacardio.2017.0175 CrossRefPubMedPubMedCentral

18.

Manson JE, Cook NR, Lee IM, Christen W, Bassuk SS, Mora S, Gibson H, Gordon D, Copeland T, D’Agostino D, Friedenberg G, Ridge C, Bubes V, Giovannucci EL, Willett WC, Buring JE, Group VR (2019) Vitamin D supplements and prevention of cancer and cardiovascular disease. N Engl J Med 380(1):33–44. https://doi.org/10.1056/nejmoa1809944 CrossRefPubMed

19.

Lamb SE, Jorstad-Stein EC, Hauer K, Becker C, Prevention of Falls Network E, Outcomes Consensus G (2005) Development of a common outcome data set for fall injury prevention trials: the Prevention of Falls Network Europe consensus. J Am Geriatr Soc 53(9):1618–1622. https://doi.org/10.1111/j.1532-5415.2005.53455.x CrossRefPubMed

20.

Khaw KT, Stewart AW, Waayer D, Lawes CMM, Toop L, Camargo CA Jr, Scragg R (2017) Effect of monthly high-dose vitamin D supplementation on falls and non-vertebral fractures: secondary and post hoc outcomes from the randomised, double-blind, placebo-controlled ViDA trial. Lancet Diabetes Endocrinol 5(6):438–447. https://doi.org/10.1016/s2213-8587(17)30103-1 CrossRefPubMed

21.

Lappe J, Watson P, Travers-Gustafson D, Recker R, Garland C, Gorham E, Baggerly K, McDonnell SL (2017) Effect of vitamin D and calcium supplementation on cancer incidence in older women: a randomized clinical trial. JAMA 317(12):1234–1243. https://doi.org/10.1001/jama.2017.2115 CrossRefPubMed

22.

Scragg R, Khaw KT, Toop L, Sluyter J, Lawes CMM, Waayer D, Giovannucci E, Camargo CA Jr (2018) Monthly high-dose vitamin d supplementation and cancer risk: a post hoc analysis of the vitamin D assessment randomized clinical trial. JAMA Oncol 4(11):e182178. https://doi.org/10.1001/jamaoncol.2018.2178 CrossRefPubMedPubMedCentral

23.

Reid IR, Horne AM, Mihov B, Gamble GD, Al-Abuwsi F, Singh M, Taylor L, Fenwick S, Camargo CA, Stewart AW, Scragg R (2017) Effect of monthly high-dose vitamin D on bone density in community-dwelling older adults substudy of a randomized controlled trial. J Intern Med 282(5):452–460. https://doi.org/10.1111/joim.12651 CrossRefPubMed

24.

Macdonald HM, Reid IR, Gamble GD, Fraser WD, Tang JC, Wood AD (2018) 25-Hydroxyvitamin D threshold for the effects of vitamin d supplements on bone density: secondary analysis of a randomized controlled trial. J Bone Miner Res 33(8):1464–1469. https://doi.org/10.1002/jbmr.3442 CrossRefPubMed

25.

Sluyter JD, Camargo CA, Waayer D, Lawes CMM, Toop L, Khaw KT, Scragg R (2017) Effect of monthly, high-dose, long-term vitamin d on lung function: a randomized controlled trial. Nutrients. https://doi.org/10.3390/nu9121353 CrossRefPubMedPubMedCentral

26.

Cazzola M, MacNee W, Martinez FJ, Rabe KF, Franciosi LG, Barnes PJ, Brusasco V, Burge PS, Calverley PM, Celli BR, Jones PW, Mahler DA, Make B, Miravitlles M, Page CP, Palange P, Parr D, Pistolesi M, Rennard SI, Rutten-van Molken MP, Stockley R, Sullivan SD, Wedzicha JA, Wouters EF, American Thoracic S, European Respiratory Society Task Force on outcomes of C (2008) Outcomes for COPD pharmacological trials: from lung function to biomarkers. Eur Respir J 31(2):416–469. https://doi.org/10.1183/09031936.00099306 CrossRefPubMed

27.

Sluyter JD, Camargo CA Jr, Stewart AW, Waayer D, Lawes CMM, Toop L, Khaw KT, Thom SAM, Hametner B, Wassertheurer S, Parker KH, Hughes AD, Scragg R (2017) Effect of monthly, high-dose, long-term vitamin D supplementation on central blood pressure parameters: a randomized controlled trial substudy. J Am Heart Assoc. https://doi.org/10.1161/jaha.117.006802 CrossRefPubMedPubMedCentral

28.

Raed A, Bhagatwala J, Zhu H, Pollock NK, Parikh SJ, Huang Y, Havens R, Kotak I, Guo DH, Dong Y (2017) Dose responses of vitamin D3 supplementation on arterial stiffness in overweight African Americans with vitamin D deficiency: a placebo controlled randomized trial. PLoS One 12(12):e0188424. https://doi.org/10.1371/journal.pone.0188424 CrossRefPubMedPubMedCentral

29.

Kumar V, Yadav AK, Lal A, Kumar V, Singhal M, Billot L, Gupta KL, Banerjee D, Jha V (2017) A randomized trial of vitamin D supplementation on vascular function in CKD. J Am Soc Nephrol 28(10):3100–3108. https://doi.org/10.1681/asn.2017010003 CrossRefPubMedPubMedCentral

30.

Stroes ES, Thompson PD, Corsini A, Vladutiu GD, Raal FJ, Ray KK, Roden M, Stein E, Tokgozoglu L, Nordestgaard BG, Bruckert E, De Backer G, Krauss RM, Laufs U, Santos RD, Hegele RA, Hovingh GK, Leiter LA, Mach F, Marz W, Newman CB, Wiklund O, Jacobson TA, Catapano AL, Chapman MJ, Ginsberg HN, European Atherosclerosis Society Consensus P (2015) Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management. Eur Heart J 36(17):1012–1022. https://doi.org/10.1093/eurheartj/ehv043 CrossRefPubMedPubMedCentral

31.

Michalska-Kasiczak M, Sahebkar A, Mikhailidis DP, Rysz J, Muntner P, Toth PP, Jones SR, Rizzo M, Kees Hovingh G, Farnier M, Moriarty PM, Bittner VA, Lip GY, Banach M, Lipid Blood Pressure, Meta-analysis Collaboration G (2015) Analysis of vitamin D levels in patients with and without statin-associated myalgia—a systematic review and meta-analysis of 7 studies with 2420 patients. Int J Cardiol 178:111–116. https://doi.org/10.1016/j.ijcard.2014.10.118 CrossRefPubMed

32.

Khayznikov M, Hemachrandra K, Pandit R, Kumar A, Wang P, Glueck CJ (2015) Statin intolerance because of myalgia, myositis, myopathy, or myonecrosis can in most cases be safely resolved by vitamin D supplementation. N Am J Med Sci 7(3):86–93. https://doi.org/10.4103/1947-2714.153919 CrossRefPubMedPubMedCentral

33.

Wu Z, Camargo CA Jr, Khaw KT, Waayer D, Lawes CMM, Toop L, Scragg R (2018) Effects of vitamin D supplementation on adherence to and persistence with long-term statin therapy: secondary analysis from the randomized, double-blind, placebo-controlled ViDA study. Atherosclerosis 273:59–66. https://doi.org/10.1016/j.atherosclerosis.2018.04.009 CrossRefPubMed

34.

Wu Z, Malihi Z, Stewart AW, Lawes CM, Scragg R (2016) Effect of vitamin D supplementation on pain: a systematic review and meta-analysis. Pain Physician 19(7):415–427PubMed

35.

Wu Z, Camargo CA Jr, Malihi Z, Bartley J, Waayer D, Lawes CMM, Toop L, Khaw KT, Scragg R (2018) Monthly vitamin D supplementation, pain, and pattern of analgesic prescription: secondary analysis from the randomized, double-blind, placebo-controlled vitamin D assessment study. Pain 159(6):1074–1082. https://doi.org/10.1097/j.pain.0000000000001189 CrossRefPubMed

36.

Malihi Z, Wu Z, Stewart AW, Lawes CM, Scragg R (2016) Hypercalcemia, hypercalciuria, and kidney stones in long-term studies of vitamin D supplementation: a systematic review and meta-analysis. Am J Clin Nutr 104(4):1039–1051. https://doi.org/10.3945/ajcn.116.134981 CrossRefPubMed

37.

Malihi Z, Lawes CMM, Wu Z, Huang Y, Waayer D, Toop L, Khaw KT, Camargo CA, Scragg R (2019) Monthly high-dose vitamin D supplementation does not increase kidney stone risk or serum calcium: results from a randomized controlled trial. Am J Clin Nutr. https://doi.org/10.1093/ajcn/nqy378 CrossRefPubMed

38.

Malihi Z, Lawes CMM, Wu Z, Huang Y, Waayer D, Toop L, Khaw KT, Camargo CA Jr, Scragg R (2018) Monthly high-dose vitamin D3 supplementation and self-reported adverse events in a 4-year randomized controlled trial. Clin Nutr. https://doi.org/10.1016/j.clnu.2018.07.034 CrossRefPubMed

39.

Sanders KM, Stuart AL, Williamson EJ, Simpson JA, Kotowicz MA, Young D, Nicholson GC (2010) Annual high-dose oral vitamin D and falls and fractures in older women: a randomized controlled trial. JAMA 303(18):1815–1822. https://doi.org/10.1001/jama.20 CrossRefPubMed

40.

Hollis BW, Wagner CL (2013) Clinical review: the role of the parent compound vitamin D with respect to metabolism and function: why clinical dose intervals can affect clinical outcomes. J Clin Endocrinol Metab 98(12):4619–4628. https://doi.org/10.1210/jc.2013-2653 CrossRefPubMedPubMedCentral

41.

Heaney RP, Armas LA (2015) Quantifying the vitamin D economy. Nutr Rev 73(1):51–67. https://doi.org/10.1093/nutrit/nuu004 CrossRefPubMed

42.

Martineau AR, Jolliffe DA, Hooper RL, Greenberg L, Aloia JF, Bergman P, Dubnov-Raz G, Esposito S, Ganmaa D, Ginde AA, Goodall EC, Grant CC, Griffiths CJ, Janssens W, Laaksi I, Manaseki-Holland S, Mauger D, Murdoch DR, Neale R, Rees JR, Simpson S Jr, Stelmach I, Kumar GT, Urashima M, Camargo CA Jr (2017) Vitamin D supplementation to prevent acute respiratory tract infections: systematic review and meta-analysis of individual participant data. BMJ 356:i6583. https://doi.org/10.1136/bmj.i6583 CrossRefPubMedPubMedCentral

43.

Jolliffe DA, Greenberg L, Hooper RL, Griffiths CJ, Camargo CA Jr, Kerley CP, Jensen ME, Mauger D, Stelmach I, Urashima M, Martineau AR (2017) Vitamin D supplementation to prevent asthma exacerbations: a systematic review and meta-analysis of individual participant data. Lancet Respir Med 5(11):881–890. https://doi.org/10.1016/s2213-2600(17)30306-5 CrossRefPubMedPubMedCentral

44.

Jolliffe DA, Greenberg L, Hooper RL, Mathyssen C, Rafiq R, de Jongh RT, Camargo CA, Griffiths CJ, Janssens W, Martineau AR (2019) Vitamin D to prevent exacerbations of COPD: systematic review and meta-analysis of individual participant data from randomised controlled trials. Thorax. https://doi.org/10.1136/thoraxjnl-2018-212092 CrossRefPubMed

45.

Scragg R (2018) Emerging evidence of thresholds for beneficial effects from vitamin D supplementation. Nutrients 1:1. https://doi.org/10.3390/nu10050561 CrossRef

46.

Rose G (1985) Sick individuals and sick populations. Int J Epidemiol 14(1):32–38CrossRefPubMed

47.

Minisola S, Colangelo L, Cipriani C, Pepe J, Cook DP, Mathieu C (2019) Screening for hypovitaminosis D: cost-effective or not? Eur J Endocrinol Eur Fed Endocr Soc 180(3):D1–D7. https://doi.org/10.1530/eje-18-0977 CrossRef

Titel: Overview of results from the Vitamin D Assessment (ViDA) study
verfasst von: R. K. R. Scragg
Publikationsdatum: 01.12.2019
Verlag: Springer International Publishing
Erschienen in: Journal of Endocrinological Investigation / Ausgabe 12/2019
Elektronische ISSN: 1720-8386
DOI: https://doi.org/10.1007/s40618-019-01056-z

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

„Jeder Fall von plötzlichem Tod muss obduziert werden!“

17.05.2024 Plötzlicher Herztod Nachrichten

Ein signifikanter Anteil der Fälle von plötzlichem Herztod ist genetisch bedingt. Um ihre Verwandten vor diesem Schicksal zu bewahren, sollten jüngere Personen, die plötzlich unerwartet versterben, ausnahmslos einer Autopsie unterzogen werden.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Schlechtere Vorhofflimmern-Prognose bei kleinem linken Ventrikel

17.05.2024 Vorhofflimmern Nachrichten

Nicht nur ein vergrößerter, sondern auch ein kleiner linker Ventrikel ist bei Vorhofflimmern mit einer erhöhten Komplikationsrate assoziiert. Der Zusammenhang besteht nach Daten aus China unabhängig von anderen Risikofaktoren.

Semaglutid bei Herzinsuffizienz: Wie erklärt sich die Wirksamkeit?

17.05.2024 Herzinsuffizienz Nachrichten

Bei adipösen Patienten mit Herzinsuffizienz des HFpEF-Phänotyps ist Semaglutid von symptomatischem Nutzen. Resultiert dieser Benefit allein aus der Gewichtsreduktion oder auch aus spezifischen Effekten auf die Herzinsuffizienz-Pathogenese? Eine neue Analyse gibt Aufschluss.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Background

Methods

Results

Conclusion

Trial registration

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 12/2019

Transoral thyroidectomy: new method with new complications’ spectrum

p38MAPK controls fibroblast growth factor 23 (FGF23) synthesis in UMR106-osteoblast-like cells and in IDG-SW3 osteocytes

Saliva versus serum cortisol to identify subclinical hypercortisolism in adrenal incidentalomas: simplicity versus accuracy

Monitoring testosterone replacement therapy with transdermal gel: when and how?

Changes in TSH levels in athyreotic patients with differentiated thyroid cancer during levothyroxine therapy: influence on dose adjustments